Genomic Health Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 8,290 shares of the firm’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $30.59, for a total value of $253,591.10. Following the completion of the sale, the chief operating officer now directly owns 39,426 shares in the company, valued at $1,206,041.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

G Bradley Cole also recently made the following trade(s):

  • On Thursday, August 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $28.87, for a total value of $144,350.00.

Genomic Health Inc. (NASDAQ:GHDX) opened at 28.91 on Thursday. The stock’s 50 day moving average is $28.21 and its 200 day moving average is $27.28. The stock’s market capitalization is $964.03 million. Genomic Health Inc. has a 12-month low of $20.05 and a 12-month high of $35.79.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.18). The business had revenue of $81.97 million for the quarter, compared to the consensus estimate of $81.27 million. Genomic Health had a negative net margin of 8.84% and a negative return on equity of 21.02%. The company’s revenue for the quarter was up 16.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.29) EPS. Equities analysts predict that Genomic Health Inc. will post ($0.47) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Institutional investors have recently modified their holdings of the company. Independent Portfolio Consultants Inc. increased its position in shares of Genomic Health by 54.5% in the second quarter. Independent Portfolio Consultants Inc. now owns 17,595 shares of the company’s stock worth $456,000 after buying an additional 6,210 shares in the last quarter. Royal Bank of Canada increased its position in Genomic Health by 6,543.0% in the first quarter. Royal Bank of Canada now owns 8,503 shares of the company’s stock worth $210,000 after buying an additional 8,375 shares in the last quarter. Renaissance Technologies LLC increased its position in Genomic Health by 54.0% in the first quarter. Renaissance Technologies LLC now owns 446,021 shares of the company’s stock worth $11,048,000 after buying an additional 156,421 shares in the last quarter. HBK Investments L P acquired a new position in Genomic Health during the first quarter worth about $886,000. Finally, Kimelman & Baird LLC increased its position in Genomic Health by 2.3% in the first quarter. Kimelman & Baird LLC now owns 21,940 shares of the company’s stock worth $543,000 after buying an additional 500 shares in the last quarter. Institutional investors and hedge funds own 88.92% of the company’s stock.

Several analysts recently issued reports on GHDX shares. Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Tuesday, October 4th. Jefferies Group raised their target price on Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, August 17th. Canaccord Genuity reissued a “buy” rating and issued a $38.00 target price on shares of Genomic Health in a research note on Friday, August 5th. Leerink Swann reissued a “buy” rating on shares of Genomic Health in a research note on Tuesday, June 21st. Finally, Bank of America Corp. set a $28.00 target price on Genomic Health and gave the stock a “sell” rating in a research note on Wednesday, August 3rd. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.50.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

5 Day Chart for NASDAQ:GHDX

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.